StreetInsider.com News Articles

Neurocrine Bio. (NBIX) PT Lowered to $187 at RBC Capital

Mon, 21 Sep 2026 08:24:53 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $187.00 (from $198.00) while maintaining a Outperform rating.

CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform

Fri, 18 Sep 2026 06:10:36 -0400

CCB Int'l initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Outperform rating.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $151.83 yesterday.

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Lippoldt Darin

Tue, 15 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27065754.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Onyia Jude

Tue, 15 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27065763.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Keswani Sanjay Chandru

Tue, 15 Sep 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260915/27065747.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Gano Kyle

Tue, 15 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27065736.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: GORMAN KEVIN CHARLES

Tue, 15 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27065743.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Cooke Julie

Tue, 15 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260915/27065714.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Delaet Ingrid

Tue, 15 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260915/27065716.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: BENEVICH ERIC

Tue, 15 Sep 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260915/27065702.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Boyer David W.

Tue, 15 Sep 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260915/27065711.html

Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: ABERNETHY MATT

Tue, 15 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260915/27065699.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: ABERNETHY MATT

Mon, 14 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260914/27059064.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: Boyer David W.

Mon, 14 Sep 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260914/27058955.html

Neurocrine Bio. (NBIX) PT Raised to $183 at Morgan Stanley

Fri, 11 Sep 2026 08:37:12 -0400

Morgan Stanley analyst Jeffrey Hung raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $183.00 (from $182.00) while maintaining a Equalweight rating.

Form 4 NEUROCRINE BIOSCIENCES For: Sep 09 Filed by: BENEVICH ERIC

Thu, 10 Sep 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260910/27049816.html

RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'

Tue, 08 Sep 2026 09:15:53 -0400

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $198.00 price target on Neurocrine Bio. (NASDAQ: NBIX).

The analyst commented: "Getting Ahead of a Catalyst-Rich 2027 - Before a Potential Run-Up; Following the recent pullback, NBIX now trades at a ~$16B cap, <4x our durable annual Ingrezza+Crenessity sales est. - implying minimal embedded value for Vykat or the pipeline. We expect strong Ingrezza +Crenessity numbers to drive 2H26 appreciation, with any improved Vykat performance further catalyzing upside - but also see potential for shares to run up into the higher density of '27 pipeline catalysts. While data from the

Neurocrine Bio. (NBIX) PT Raised to $253 at Citi

Thu, 03 Sep 2026 05:02:18 -0400

Citi analyst Yigel Nochomovitz raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $253.00 (from $249.00) while maintaining a Buy rating.

Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley

Thu, 13 Aug 2026 08:09:11 -0400

Morgan Stanley analyst Jeffrey Hung lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $182.00 (from $196.00) while maintaining a Equalweight rating.

Neurocrine's Ingrezza study shows quality-of-life gains in TD patients

Wed, 12 Aug 2026 08:30:55 -0400

Neurocrine Biosciences (NASDAQ: NBIX) announced the publication of results from its KINECT-PRO Phase 4 open-label study, showing that once-daily Ingrezza (valbenazine) capsules produced improvements in patient-reported quality of life and daily functioning among people with tardive dyskinesia (TD). The findings were published in CNS Spectrums.

The study enrolled 59 patients who received Ingrezza at doses of 40 mg, 60 mg, or 80 mg once daily for up to 24 weeks. Fifty-two patients completed the Week 24 visit, with 45 included in efficacy analyses. At baseline, approximately 41% of patients had mild TD movement severity, while 59% had moderate or severe TD.

Mean

Neurocrine's Ingrezza study shows quality-of-life gains in TD patients

Wed, 12 Aug 2026 08:30:55 -0400

Mean

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living

Wed, 12 Aug 2026 08:30:00 -0400

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes
Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity
Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity
Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and